EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment for schizophrenia and other dopamine system dysfunctions



Treatment for schizophrenia and other dopamine system dysfunctions



Official Gazette of the United States Patent & Trademark Office Patents 1246(3), May 15



Methods and compositions for the treatment of positive and negative symptoms of schizophrenia and tardive dyskinesia are provided. Compositions include 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its analogs, and/or pyridinium ions thereof, administered in amounts sufficient to reduce dopamine levels in subcortical areas of the brain without causing symptoms of Parkinson's disease. One course of treatment can result in permanent or long-term amelioration of symptoms.

(PDF 0-2 workdays service: $29.90)

Accession: 035980243

Download citation: RISBibTeXText



Related references

Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor. Neurotoxicity Research 6(1): 63-71, 2004

Role of dopamine D3 receptor and dopamine transporter polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. American Journal of Medical Genetics 124B(1): 1-5, January 1, 2004

Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 124b(1): 1-5, 2003

Elevated thalamic dopamine: possible link to sensory dysfunctions in schizophrenia. Schizophrenia Bulletin 13(4): 589-604, 1987

Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia. International Journal of Molecular Sciences 16(12): 30144-30163, 2016

Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology 62(3): 1342-1348, 2012

The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention. Schizophrenia Bulletin, 2018

Adenosine-dopamine interaction in the ventral striopallidal system A new focus for the treatment of schizophrenia. Society for Neuroscience Abstracts 20(1-2): 1277, 1994

Treatment of cognitive dysfunctions and behavioral deficits in schizophrenia. Schizophrenia Bulletin 18(1): 21-26, 1992

Limbic system dysfunctions in schizophrenia and mania using 18F-fluorodeoxyglucose and positron emission tomography. Schizophrenia Research 18(2-3): 197, 1996

Limbic system dysfunctions in mania and schizophrenia using 18F-fluorodeoxyglucose and positron emission tomography. European Psychiatry 11(Supp-S4): 260-261, 1996

Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins. Biological Psychiatry 56(6): 427-440, 2004

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41(1): 1-24, 1991

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity a hypothesis for the etiology of schizophrenia. Society for Neuroscience Abstracts 15(2): 1002, 1989

Effects of the 141C insertion/deletion polymorphism in the dopamine D2 receptor gene on the dopamine system in the striatum in patients with schizophrenia. Psychiatry Research 264: 116-118, 2018